ATLASApimeds Pharmaceuticals US (APUS) earnings date: Nov 11, 2026
Apimeds Pharmaceuticals US (APUS) reports earnings for the quarter ended Sep 30, 2026 on Wed, Nov 11, 2026.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on APUS
| Last price | $2.86 (-5.0%) |
|---|---|
| Normal 1-day range (±1σ) | ±11.0% |
| Earnings beat history | Beat the EPS estimate in 3 of the last 5 reports |
These figures come from the same calibrated model and valuation as the Apimeds Pharmaceuticals US stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Apimeds Pharmaceuticals US reports on Nov 11, 2026. One email the day before, with ATLAS’s read on Apimeds Pharmaceuticals US. You can switch it off at any time.
Alert me before APUS reportsFree to start. Creating an account takes under a minute.
Notify me when Apimeds Pharmaceuticals US reports
Track APUS free Add Apimeds Pharmaceuticals US to a free ATLAS watchlist and see its next report date in one place.
APUS earnings at a glance
| Next report (confirmed) | Wed, Nov 11, 2026 |
|---|---|
| Time | Not stated |
| Period | Quarter ended Sep 30, 2026 |
| Last report | Jul 22, 2026 · Beat |
| Beat rate (last 5 reports) | 3 of 5 (60%) |
| Average EPS surprise | +54.5% |
| Average move around a report | ±7.2% (last 5) |
| Sector | Healthcare · Drug Manufacturers - Specialty & Generic |
Apimeds Pharmaceuticals US earnings history: last 5 reports
Apimeds Pharmaceuticals US last reported on Jul 22, 2026: EPS of $2.99 against an estimate of $2.91 (+2.7% surprise), a beat.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Jul 22, 2026 | $2.91 | $2.99 | +2.7% | Beat | -11.3% |
| Nov 12, 2025 | $0.18 | $0.64 | +255.6% | Beat | +4.5% |
| Oct 22, 2025 | $2.63 | $2.68 | +1.9% | In line | -8.7% |
| Oct 13, 2025 | $0.02 | $0.03 | +50.0% | Beat | -4.3% |
| Sep 24, 2025 | $1.03 | $0.64 | -37.9% | Miss | -7.1% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for APUS
See the fair value, the probability range and the earnings history of Apimeds Pharmaceuticals US on its ATLAS page.
Apimeds Pharmaceuticals US (APUS) stock analysisPlans from €3.99 a month.
Apimeds Pharmaceuticals US earnings: frequently asked questions
When does Apimeds Pharmaceuticals US (APUS) report earnings?
Apimeds Pharmaceuticals US is scheduled to report on Wednesday, November 11, 2026 (the time of day has not been stated). ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
How often does APUS beat earnings estimates?
Of its last 5 reports with a recorded result, Apimeds Pharmaceuticals US beat the EPS estimate 3 times; the average surprise was +54.5%. Past results do not predict the next one.
How much does APUS move around earnings?
Over its last 5 reports the stock moved an average of 7.2% (absolute, from the close before the report day to the close after it), and finished higher 1 of 5 times.
Did Apimeds Pharmaceuticals US beat earnings estimates last quarter?
Apimeds Pharmaceuticals US last reported on Jul 22, 2026: EPS of $2.99 against an estimate of $2.91 (+2.7% surprise), a beat.
How much does APUS usually move in a day?
On a normal trading day the ATLAS model puts APUS’s one-day range at about ±11.0%, with a 47% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Wed, Nov 11, 2026
Educational information, not investment advice. Disclaimer